Lifeboat Foundation

Today the U.S. Food and Drug Administration announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies.

The framework — outlined in a suite of four guidance documents — builds upon the FDA’s existing risk-based regulatory approach to more clearly describe what products are regulated as drugs, devices, and/or biological products. Further, two of the guidance documents propose an efficient, science-based process for helping to ensure the safety and effectiveness of these therapies, while supporting development in this area. The suite of guidance documents also defines a risk-based framework for how the FDA intends to focus its enforcement actions against those products that raise potential significant safety concerns. This modern framework is intended to balance the agency’s commitment to safety with mechanisms to drive further advances in regenerative medicine so innovators can bring new, effective therapies to patients as quickly and safely as possible. The policy also delivers on important provisions of the 21^st Century Cures Act.

We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine.

https://youtube.com/watch?v=yiaKNmUIcqs

The makers of the Argus II bionic eye are working on a new interface that sits directly on the user’s brain.

Gene therapy and stem cells could treat Kidney Failure.

Click on photo to start video.

Kizoo, part of the Forever Healthy Foundation, has announced today that it will be supporting biotech company LIfT Biosciences, a company that focuses on creating a new generation of cancer therapies that use our own immune systems.

Turning our immune system into a cancer-fighting machine

Led by CEO Alex Blyth, LIfT Biosciences is developing a new type of cancer immunotherapy approach that uses neutrophils, a type of immune cell, to seek and destroy all types of solid tumors.

WASHINGTON — Blue Origin filed a protest with the U.S. Government Accountability Office on Monday challenging the Air Force’s plan to select two providers in the next procurement of launch services under the National Security Space Launch program.

Blue Origin, a rocket manufacturer and suborbital spaceflight company founded by Jeff Bezos, filed what is known as a “pre-award” protest with the GAO, arguing that the rules set by the Air Force do not allow for a fair and open competition.

“The Air Force is pursuing a flawed acquisition strategy for the National Security Space Launch program,” states a Blue Origin fact sheet that outlines the reasons for the protest.

Our cells are more malleable than we thought – and by transforming them inside the body, we can mend broken hearts or even degenerating brains from within.

We are happy to announce our support for LIfT Biosciences. LIfT is developing the world’s first cell therapy to destroy all solid tumors, irrespective of strain or mutation.

The team lead by Alex Blyth is achieving this by building the world’s 1st cell bank of innately cancer-killing neutrophils. Congrats!

kizoo.com/en

The supermassive black hole at the heart of our galaxy has suddenly started flashing brighter than we have ever seen it, and astronomers don’t know why.